Iepsen EW, Lundgren JR, Hartmann B et al (2015) GLP-1 receptor agonist treatment increases bone formation and prevents bone loss in weight-reduced obese women
For example, in June 2025, Connecticut Attorney General released a statement warning businesses of allegedly or potentially unfair and deceptive conduct related to compounding of GLP-1 medications
Although we did not look at sex differences in discontinuation reasons, research work has shown that women experience nausea and vomiting (side effects) at 2.5-fold higher rates than men ( 11 )
"Lilly's phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight"
What units actually mean on a semaglutide syringe A unit is a volume measurement, not a dose measurement
The glucagon-like peptide-1 receptor (GLP-1R), a class B1 subfamily GPCR, signals primarily through the stimulatory G (Gs) protein